Literature DB >> 12007517

Central pathways controlling micturition and urinary continence.

Bertil F M Blok1.   

Abstract

The central control of micturition and urinary continence in cats and humans is organized in a similar manner. In cats, 4 areas in the brainstem and diencephalon are implicated in the control of micturition: (1) the pontine micturition center or Barrington area directly excites bladder motoneurons in the sacral cord during micturition; at the same time, it inhibits indirectly, via inhibitory gamma-aminobutyric acidergic and glycinergic interneurons in the medial sacral cord, the external urethral sphincter motoneurons; (2) the pontine continence center activates the external urethral sphincter motoneurons during continence; (3) the midbrain periaqueductal gray receives bladder filling information; and (4) the hypothalamus, in the beginning of micturition. According to positron emission tomography studies, in humans, the same supraspinal regions are active during micturition. Furthermore, the human cingulate and prefrontal cortices are activated during both micturition and continence, indicating that these areas are important for the onset of micturition, but not for the reflex itself. The primary motor cortex of the pelvic floor is important for voluntary pelvic floor contraction, but it is not involved in normal urinary continence.

Entities:  

Mesh:

Year:  2002        PMID: 12007517     DOI: 10.1016/s0090-4295(01)01633-8

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  24 in total

Review 1.  [The ice water test and bladder cooling reflex. Physiology, pathophysiology and clinical importance].

Authors:  T Hüsch; T Neuerburg; A Reitz; A Haferkamp
Journal:  Urologe A       Date:  2016-04       Impact factor: 0.639

2.  Roles for pain modulatory cells during micturition and continence.

Authors:  Madelyn A Baez; Thaddeus S Brink; Peggy Mason
Journal:  J Neurosci       Date:  2005-01-12       Impact factor: 6.167

3.  Cerebral control of the bladder in normal and urge-incontinent women.

Authors:  Derek Griffiths; Stasa D Tadic; Werner Schaefer; Neil M Resnick
Journal:  Neuroimage       Date:  2007-05-18       Impact factor: 6.556

4.  Prospective, randomized, double-blind study of safety and tolerability of intravesical resiniferatoxin (RTX) in interstitial cystitis (IC).

Authors:  Tony Y H Chen; Jacques Corcos; Michel Camel; Yves Ponsot; Le Mai Tu
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2005-04-08

Review 5.  Botulinum neurotoxin-A treatment of lower urinary tract symptoms in multiple sclerosis.

Authors:  Oussama El Yazami Adli; Jacques Corcos
Journal:  Can Urol Assoc J       Date:  2014-01       Impact factor: 1.862

6.  The Impact of Duration of Complaints on Successful Outcome of Sacral Neuromodulation.

Authors:  Ranjana Jairam; Jamie Drossaerts; Gommert van Koeveringe; Philip van Kerrebroeck
Journal:  Urol Int       Date:  2017-05-06       Impact factor: 2.089

7.  Responses of functional brain networks to bladder control in healthy adults: a study using regional homogeneity combined with independent component analysis methods.

Authors:  Dongqing Pang; Yi Gao; Limin Liao
Journal:  Int Urol Nephrol       Date:  2021-02-01       Impact factor: 2.370

8.  Surgical options for drug-refractory overactive bladder patients.

Authors:  Jonathan S Starkman; Christopher P Smith; David R Staskin
Journal:  Rev Urol       Date:  2010

9.  Connection between expression of inducible nitric oxide synthase (iNOS) in skull base chordoma and lower urinary tract symptoms.

Authors:  Reza Akhavan-Sigari; Helmut Ostertag; Veit Rohde; Hossein Tezval
Journal:  Int Urol Nephrol       Date:  2014-08-12       Impact factor: 2.370

10.  Bladder dysfunction in mice with experimental autoimmune encephalomyelitis.

Authors:  Cengiz Z Altuntas; Firouz Daneshgari; Guiming Liu; Adebola Fabiyi; Michael Kavran; Justin M Johnson; M Fatih Gulen; Ritika Jaini; Xiaoxia Li; Tara L Frenkl; Vincent K Tuohy
Journal:  J Neuroimmunol       Date:  2008-10-15       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.